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Objective: To evaluate the prevalence of hepatitis C virus (HCV) infection in high risk juvenile
systemic lupus erythematosus (JSLE).
Study design: Forty low income JSLE patients (6M:34F; mean age 19 ± 4.4 yrs; mean disease
duration 6 ± 3.2 yrs) were studied. Twenty healthy children and adolescents matched for
social economical level were included as controls. Anti-HCV tests were performed using
a  third generation microparticle enzyme immunoassay. Inclusion criterion was low social
economical level.
Results: The frequencies of anti-HCV antibody were low and comparable between JSLE and
control group (2.5% vs. 0, p = 1.0). JSLE patients had signiﬁcantly more risk factors for HCV
infection compared to the control group, including immunosuppressive treatment (90% vs.
0,  p < 0.0001), hospitalization (50% vs. 12.5%, p = 0.0006) and invasive procedures (47.5% vs.
12.5%, p = 0.001).
Conclusions: The observed low frequency of anti-HCV antibodies in high risk JSLE suggests
that  this virus does not seem to have a relevant role in the pathogenesis of this disease.
© 2016 Elsevier Editora Ltda. All rights reserved.
Anticorpos  contra  o  vírus  da  hepatite  C  em  pacientes  de  alto  risco
com  lúpus  eritematoso  sistêmico  de  início  juvenil
alavras-chave:
írus contra a hepatite C
r  e  s  u  m  o
Objetivo: Avaliar a prevalência de infecc¸ão pelo vírus da hepatite C (VHC) em pacientes de
alto risco com lúpus eritematoso sistêmico de início juvenil (LESJ).
nti-VHC
úpus eritematoso sistêmico
e início juvenil
Desenho do estudo: Foram estudados 40 pacientes de baixa renda com LESJ (6H: 34M, com
média  de 19 ± 4,4 anos; durac¸ão média da doenc¸a de 6 ± 3,2 anos). Incluíram-se no grupo
controle 20 crianc¸as e adolescentes saudáveis pareados por nível socioeconômico. Fizeram-
se  testes anti-VHC com um ensaio imunoenzimático de micropartículas de terceira gerac¸ão.
O  critério de inclusão foi o baixo nível socioeconômico.
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Resultados: As frequências de anticorpos anti-VHC foram baixas e comparáveis entre os
grupos LESJ e controle (2,5% versus 0, p = 1). Os pacientes com LESJ tinham signiﬁcativa-
mente mais fatores de risco para infecc¸ão por VHC em comparac¸ão com o grupo controle,
incluindo tratamento imunossupressor (90% versus 0, p < 0,0001), internac¸ão (50% versus
12,5%, p = 0,0006) e procedimentos invasivos (47,5% versus 12,5%, p = 0,001).
Conclusões: A baixa frequência de anticorpos anti-VHC observada nos pacientes de alto risco
com  LESJ sugere que esse vírus não parece ter um papel relevante na patogênese dessa
doenc¸a.
© 2016 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Systemic lupus erythematosus (SLE) is a complex autoim-
mune disease, characterized by a wide spectrum of multi-
organ involvement and laboratorial abnormalities. The
disease is characterized by several immunoregulatory alter-
ations that culminate to an exacerbated production of
autoantibodies. The pathogenesis of SLE is still unclear but
some infectious agents, including hepatitis C virus (HCV), may
be involved as possible triggering agents.1,2
HCV is a linear single stranded RNA virus of the Flaviviri-
dae family, which has an extensive genomic variability.3 It is
well known that HCV infection is one of the most common
causes of chronic viral hepatitis.3 Furthermore, several extra-
hepatic immunological manifestations have been associated
to HCV.4–6
In fact, HCV is an important inductor of autoantibody
production such as antinuclear antibodies (ANA),6 rheuma-
toid factors and cryoglobulins7 and a possible association
of this virus with autoimmune rheumatic diseases, includ-
ing Sjögren’s syndrome and vasculitis has been previously
described.8,9 In adult SLE patients some reports point out to
a higher prevalence of anti-HCV antibodies (3–13%) than the
expected for the general population1,10,11 raising the possi-
bility that exposure to this infection agent may contribute to
disease expression.
There are, however, no data regarding the association of
HCV in juvenile SLE (JSLE). Therefore, the aim of this study
was to investigate the prevalence of sera anti-HCV antibodies
in high risk JSLE patients.
Patients  and  methods
Fifty consecutive low income subjects who fulﬁlled the Ameri-
can College of Rheumatology (ACR) classiﬁcation criteria12 for
JSLE followed at our Pediatric Rheumatology Unit were initially
selected. Ten of them were excluded due to incomplete charts
and irregular follow-up. The remaining forty eligible patients
were included in the study. Twenty healthy subjects matched
by socioeconomic status (according to a standardized ques-
tionnaire of Associac¸ão Brasileira dos Institutos de Pesquisa de
Mercados) were selected for the control group.13
High HCV risk factor was deﬁned by low income [lowest
Brazilian socio-economic classes (C, D or E)] and presence of
one or more  risk factors: hospitalizations, invasive diagnosticor therapeutic procedures (intravenous medications, biop-
sies or endoscopic diagnostic methods), immunosuppressive
drugs, blood products transfusions, intravenous drugs use and
promiscuous sexual activity (≥3 sexual partners per year).14
This study was approved by the Local Ethical Committee of
our University Hospital.
For JSLE patients, clinical manifestations at disease diag-
nosis and at the moment of the study were searched. SLE
disease activity at study entry was recorded for all patients
using the SLE Disease Activity Index (SLEDAI) score15 and an
index greater than 8 was considered as active JSLE.
A systematic physical examination was performed to ﬁnd
signs of hepatic impairment, including cutaneous stigmata,
liver enlargement, ascites and/or jaundice.
Detection  of  anti-HCV  antibodies
Testing for anti-HCV antibodies was performed in sera from all
JSLE patients and controls using a third generation immunen-
zyme assay with MEIA – microparticle enzyme immunoassay
(ELISA-3; Axsym System version 3.0; Abbott, Abbott Park,
IL). The MEIA test is a variation of the standardized enzy-
matic immunoabsorbancy assay (EIA) developed to detect
speciﬁc antibodies against structural and non-structural pro-
teins of virus genome. This method uses plate containing
recombinant HCV antigens Hcr43, c200, c100-3, pL33c and
NS5.
Laboratory  autoimmune  and  hepatic  proﬁle
All subjects were screened for anti-nuclear antibodies (ANA)
by indirect immunoﬂuorescence using HEp-2 cells as substrate
and anti-dsDNA antibody by indirect immunoﬂuorescence
using Crithidia luciliae.  Further serologic evaluation included
testing for Ro and La autoantibodies by countercurrent
immunoelectrophoresis, anti-Sm and anti-ENA antibodies by
hemmaglutination, IgM and IgG anti-cardiolipin by ELISA
and rheumatoid factor by latex ﬁxation and Waaler–Rose
tests. In addition, protein electrophoresis, cryoglobulins
(by cryoprecipitation) and total complement CH100 (by
immunohemolysis) including C3 and C4 fractions (by radial
immunodiffusion) were investigated.
Laboratory liver involvement was deﬁned as the presence
of elevated liver enzymes [aspartate aminotransferase (AST),
alanino aminotransferase (ALT) and alkaline phosphatase]
and bilirubin at least twice the normal values in two different
occasions.
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Table 1 – Demographic data and risk factors for HCV infection in 40 JSLE patients and 20 controls.
JSLE patient Controls p-Value
n = 40 n = 20
n (%)
Demographic data
Female gender, n (%) 34 (85) 16 (80) 0.72
Mean disease duration, years 6 ± 3.2 –
Caucasian race, n (%) 36 (90) 14 (70) 0.07
Risk factor
Blood and blood components transfusion 0 0 1.0
Sexual promiscuity 0 0 1.0
Drug addiction 0 0 1.0
Low income 40  (100) 20 (100) 1.0
Immunosuppressive drug 36 (90) 0 <0.0001
Previous hospitalization 20 (50) 2 (10) 0.004
Number of invasive procedures 19 (47.5) 3 (15) 0.022
JSLE, juvenile systemic lupus erythematosus; HCV, hepatitis C virus.
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ttatistical  analysis
esults are presented as the mean ± standard deviation for
ontinuous variables and number (%) for categorical variables.
ifferences between categorical variables were assessed by
isher’s exact test. In all statistical tests signiﬁcance was con-
idered with a p value < 0.05.
esults
hirty four (85%) JSLE patients and 16 (80%) control subjects
ere female with a mean age of 19 ± 4.4 years and 17 ± 3.9
ears respectively (p > 0.05). The mean disease duration was
 ± 3.2 years.
Frequencies of positive serum anti-HCV were low and com-
arable in JSLE and control group (2.5% vs. 0, p = 1.0). JSLE
atients had signiﬁcantly more  risk factors for HCV infection
ompared to the control group, including immunosuppress-
ve treatment (90% vs. 0, p < 0.0001), hospitalization (50% vs.
2.5%, p = 0.0006) and invasive procedures (47.5% vs. 12.5%,
 = 0.001) (Table 1). None of them had history of contami-
ated blood product transfusion or sexual relation with a HCV
ndividual.
All 47 JSLE patientsh´ospitalizations were due to either bac-
erial infections or to disease relapses and for the control
roup, the 5 hospitalizations were due to invasive procedures.
The only JSLE patient with detectable anti-HCV was a
3 year-old female patient with normal liver ultrasound in
pite of slightly elevated transaminases levels (AST 61 IU/L,
LT 58 IU/L) and hypergammaglobulinemia. Her complement
evels were normal, ANA was positive (1/200) and all other
utoantibodies including antiliver antibodies and cryoglobu-
ins were persistently negative. At the moment of the study,
he had a mild malar rash, photosensitivity and arthri-
is with a SLEDAI <8 in spite of taking low dose GC and
hloroquine.
The analysis of JSLE clinical manifestations demonstrated:
0 (100%) cutaneous and joints, 18 (46%) renal, 18 (46%) hema-
ological and 15 (38%) neurological. More  than one third of JSLEpatients (15/39; 38%) had active disease (SLEDAI ≥8). Half of
them were on high doses of glucocorticoid (GC), varying from
0.5 to 1.0 mg/kg/day, and 90% were under immunosuppressive
treatment for a mean period of 1.5 ± 0.5 years [azathioprine in
22 (56%), methotrexate in 2 (5%) and cyclophosphamide in 12
(31%); 4 were on monthly GC pulse therapy].
Further laboratory analysis revealed that ten (26%) JSLE
children had hypergammaglobulinemia and 12 (31%) had low
complement levels compared to none in the control group
(p < 0.05). Cryoglobulins were negative in sera from all JSLE and
controls. ANA, anti-dsDNA, anti-Sm and anti-Ro were posi-
tive in sera from 100%, 50%, 27.5% and 17.5% of JSLE patients,
respectively. Autoantibodies were uniformly negative in con-
trol group.
Discussion
To our knowledge, this is the ﬁrst study to demonstrate a low
frequency of anti-HCV serology in a population of high risk
JSLE patients from a tertiary University Hospital.
A limitation of the present study is that nowadays all
adolescents and young adults are under risk of sexually trans-
mitted diseases, including hepatitis C. This is a worldwide
problem, and this issue is important not only to lower income
families but to all families. Moreover, the low number of
subjects in the control group herein hampers deﬁnitive con-
clusions regarding HCV in healthy subjects.
The prevalence of HCV infection among blood donors
varies in different Brazilian geographic areas from 0.8% in
smaller cities such as Curitiba, Paraná to 4.78% in our largest
city São Paulo.16,17 Data regarding HCV infection in healthy
children and adolescents are however worldwide scarce.
A study conducted by Martins18 in Goiânia, Middle West
of Brazil, revealed a prevalence of anti-HCV antibodies in
this age bracket varying from 0.2 to 3%, similarly to chil-
dren from a tertiary pediatric center in London, England
(1.97%).19
The low frequency of these antibodies reported herein
for JSLE was unexpected due to the fact that all patients
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had low social levels and at least one additional known
risk factor for HCV transmission such as immunosuppress-
ive drugs use, hospitalizations and invasive interventions.18,20
This low prevalence may be partially explained by the fact
that patients were predominantly female and the virus
seems to be inﬂuenced by gender being more  frequent in
men.4 Accordingly, Karakoc et al. reported a frequency of
2.6% of anti-HCV by ELISA in a cohort of 38 SLE female
patients, similar to the control population of the same
region.21 Moreover, in our Rheumatology outpatient clinic,
JSLE patients are routinely oriented regarding sexual activity
and protection against sexually transmitted diseases, there-
fore the low frequency of anti-HCV serology observed in
the JSLE group can be related to a better education of the
patients.
On the other hand, the methodology employed does not
seem to account for the nearly absence of this reactivity in
the present study since microparticles are used to increase
the reactant surface allowing high levels of sensitivity and
speciﬁcity.22 In fact, none of our 15 patients with active disease
(elevated SLEDAI index) revealed a positive test for anti-HCV
in spite of previous report of false positive anti-HCV serology
related to lupus activity.5,11,23
Additionally, HCV has also been associated to a high
variety of extra hepatic manifestations including membra-
noproliferative glomerulonephritis, porphyria cutanea tarda,
lychen planus and thyroiditis.4–9 The notable capacity of HCV
to induce autoantibodies has aroused particular interests
in the possible association between SLE and HCV chronic
hepatitis.6 In fact, lupus patients concurrently infected by
HCV were reported to express distinct features with lower
frequency of cutaneous involvement and anti-dsDNA anti-
bodies titers and higher frequency of liver injuries,24 a
pattern also observed in the only patient with this con-
dition reported in the present study. Cryoglobulins are
also frequently found in HCV positive contrasting to HCV-
negative SLE patients,25 although not observed in our
patient.
In conclusion, this study suggests that HCV does not seem
to represent an important complication in JSLE. The possible
relevance of this virus in lupus manifestations remains to be
determined.
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